EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database

Xin Zheng, Yang Peng, Yang-Xue Ou, Bi-Bo You, Lu Zhang, Yuan Cheng, Mo Cheng, Pu Xiang

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1698293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Xin Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dianjiang People's Hospital of Chongqing, Chongqing, China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Ceftazidime/avibactam (CZA), a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam, was widely used in the treatment of multidrug-resistant (MDR) Gram-negative bacterial pathogens. In light of the growing prevalence of MDR Gram-negative bacterial infection, it is imperative to gain a deeper understanding of the true extent of adverse events (AEs) associated with CZA.

Methods

AE reports primarily associated with CZA were retrieved from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2015 to the first quarter of 2025, and all AEs were extracted. AE signal detection was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) methods. Additionally, a multivariable logistic regression analysis was performed to evaluate the safety of CZA combined with meropenem, explicitly adjusting for confounders such as age, sex, and concomitant nephrotoxins.

Results

A total of 2,444 AE reports with CZA as the preferred suspected drug were obtained, identifying 89 preferred terms (PTs) involving 24 system organ classes (SOCs). The ratio of males to females was approximately two times higher in all cases, with the highest number of reports originating from China. Some significant AE signals have been revealed by four methods, including renal and urinary disorders ( n = 112, ROR 2.49, PRR 2.43, EBGM 2.43, IC 1.28) and hepatobiliary disorders ( n = 98, ROR 5.04, PRR 4.88, EBGM 4.88, IC 2.29). Regarding combination therapy with meropenem, multivariable analysis revealed a specific safety signal: the risk of respiratory failure remained significantly elevated [adjusted OR (aOR) 3.26, P = 0.038] independent of baseline severity. Conversely, acute kidney injury showed no significant association (aOR 1.07, P = 0.868), suggesting that the respiratory risk is pharmacodynamically driven rather than a result of generalized clinical deterioration.

Conclusion

The present study identified significant and novel AEs signals for CZA. Notably, the specific association between the CZA-meropenem combination and respiratory failure warrants vigilant clinical monitoring, distinct from general disease progression risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsDrug CombinationsUnited StatesHumansUnited States Food and Drug AdministrationDatabases, FactualGram-Negative Bacterial Infectionsbeta-Lactamase Inhibitors

Stichwörter der Autor:innen

FAERSadverse eventsceftazidime/avibactamcombinationrespiratory failuresafety signals

Substanzen

CeftazidimeAzabicyclo CompoundsDrug Combinationsavibactam, ceftazidime drug combinationAnti-Bacterial Agentsbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Dianjiang People's Hospital of Chongqing, Chongqing, China.
  • Department of Pharmacy, Chongqing Dianjiang County Hospital of Traditional Chinese Medicine, Dianjiang, Chongqing, China.

Zitieren

APA

Zheng, X., Peng, Y., Ou, Y. X., You, B. B., Zhang, L., Cheng, Y., Cheng, M., & Xiang, P. (2026). Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1698293

Vancouver

Zheng X, Peng Y, Ou YX, You BB, Zhang L, Cheng Y, et al. Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1698293

BibTeX
@article{Zheng2026,
  author = {Zheng, Xin and Peng, Yang and Ou, Yang-Xue and You, Bi-Bo and Zhang, Lu and Cheng, Yuan and Cheng, Mo and Xiang, Pu},
  title = {Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1698293}
}
Kostenlos starten →